WO2002071874A2 - Composition improving age-related physiological deficits and increasing longevity - Google Patents
Composition improving age-related physiological deficits and increasing longevity Download PDFInfo
- Publication number
- WO2002071874A2 WO2002071874A2 PCT/EP2002/002862 EP0202862W WO02071874A2 WO 2002071874 A2 WO2002071874 A2 WO 2002071874A2 EP 0202862 W EP0202862 W EP 0202862W WO 02071874 A2 WO02071874 A2 WO 02071874A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antioxidant
- food composition
- composition according
- molecule
- energy metabolism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- Composition improving age-related physiological deficits and increasing longevity.
- This invention relates to a composition for improving age-related physiological deficits and extending life span in mammals.
- the invention also relates to a method for improving the condition of elderly mammals, particularly by preventing or restoring the age-related metabolic changes particularly those bound to mitochondria dysfunction.
- ROS reactive oxygen species
- Oxidative damage to mitochondria DNA increases with aging (Beckman KB, Ames BN (1999) MutatRes. 424 (l-2):51-8) along with the oxidation of glutathione (GSH) a major intracellular antioxidant system, which plays an important role in protection against age-related mt DNA oxidative damage.
- GSH glutathione
- a substantial increase in protein oxidation is also observed upon aging (Stadtman ER. (1992), Science 257 (5074): 1220-4).
- Age-related increase in the amount of long chain polyunsaturated fatty acids has been linked to the high peroxidizability of the mitochondria lipids upon aging.
- cardiolipin a phospholipid found principally in mitochondria, which fatty acid composition tends to shift towards a more unsaturated state with substitution of 18:2 acyl chains with the more peroxidizable 22:4 and 22:5 upon aging (Laganiere S, Yu BP (1993), Gerontology 39 (1):7-18).
- the mitochondria content in cardiolipin has also been reported to decrease with age.
- Cardiolipin interacts with many components of the mitochondria inner membrane such as Cytochrome oxidase, transporters/ translocators (ADP/ATP, phosphate, pyruvate, camitine, etc) and plays an active role in their activity (Hoch FL. (1992) Biochim Biophys Acta.
- the mitochondria energy metabolism depends upon the transport of metabolites such as pyruvate across the mitochondria inner membrane. Pyruvate transport is carrier-mediated
- CR caloric restriction
- the present invention provides a food composition intended to prevent or restore age-related functional deficits in mammals by reversing age-related gene expression alterations, which comprises a combination being able to mimic the effects of caloric restriction on gene expression, said combination containing at least one molecule that stimulates energy metabolism of the cell and at least one antioxidant.
- the molecule that stimulates energy metabolism is any nutrient improving energy production in mitochondria, such as L-carnitine, creatine, fatty acids (mono and polyunsaturated, particularly omega-3 fatty acids), cardiolipin, nicotinamide, carbohydrate and natural sources thereof, for example.
- nutrient improving energy production in mitochondria such as L-carnitine, creatine, fatty acids (mono and polyunsaturated, particularly omega-3 fatty acids), cardiolipin, nicotinamide, carbohydrate and natural sources thereof, for example.
- the antioxidant aims to prevent oxidative damage that can result from the disruption of the ATP/ADP and/or NAD+ NADH homeostasis due to the increased substrate availability / utilization in the aged mitochondria.
- antioxidants sources of thiols, compounds that decrease protein oxidation and compounds that upregulate cell antioxidant defenses are preferably used.
- the food composition may be a complete and nutritionally balanced food for human or animal. It can also be a dietary supplement, for example.
- the food composition according to the present invention can prevent or delay mitochondrial dysfunctions occuring during aging by modulating and/or regulating expression of genes linked to energy metabolism. It can also provide multiple benefits by improving age-related functional deficits e.g. in skeletal and cardiac muscle function, vascular function, cognitive function, vision, hearing, olfaction, skin and coat quality, bone and joint health, renal health, gut function, immune function, insulin sensitivity, inflammatory processes, cancer incidence and ultimately increasing longevity in pets.
- age-related functional deficits e.g. in skeletal and cardiac muscle function, vascular function, cognitive function, vision, hearing, olfaction, skin and coat quality, bone and joint health, renal health, gut function, immune function, insulin sensitivity, inflammatory processes, cancer incidence and ultimately increasing longevity in pets.
- this invention relates to the use of a combination being able to mimic the effects of caloric restriction on gene expression, which comprises at least one molecule that stimulates energy metabolism of the cell and at least one antioxidant, for the preparation of a composition intended to prevent or restore age-related functional deficits in mammals.
- this invention provides a method to prevent or restore age- related functional deficits in maimnals, comprising administering to the mammal, a food composition comprising a combination being able to mimic the effects of caloric restriction on gene expression, said combination containing at least one molecule that stimulates energy metabolism of the cell and at least one antioxidant.
- the said composition may be administered to the mammal as a supplement to the normal diet or as a component of a nutritionally complete food. It is preferred to include the nutritional agent in a nutritionally complete food.
- a food composition intended to prevent or restore age-related functional deficits in mammals by reversing age-related gene expression alterations which comprises a combination being able to mimic the effects of caloric restriction on gene expression, said combination containing at least one molecule that stimulates energy metabolism of the cell and at least one antioxidant.
- said molecule stimulates in particular energy metabolism of the mitochondria.
- the molecule that stimulates energy metabolism of the cell and in particular the energy metabolism of the mitochondria may be L-camitine, creatine, fatty acids (nono or polyunsaturated fatty acids, particularly omega-3 fatty acids), cardiolipin, nicotinamide, carbohydrate and natural sources thereof, for example.
- the amount of said molecule is of at least lmg per kg of body weight per day, more preferably from lmg to 1 g per kg of body weight per day.
- the antioxidants are compounds that decrease protein oxidation (e.g. prevent formation of protein carbonyls). They may be sources of tl iols (e.g. Lipoic acid, cysteine, cystine, methionine, S-adenosyl-methionine, taurine, glutathione and natural sources thereof), or compounds that upregulate their biosynthesis in vivo, for example.
- the antioxidant according to the invention may be used either alone or in association with other antioxidants such as vitamin C, vitamin E (tocopherols and tocotrienols), carotenoids (carotenes, lycopene, lutein, zeaxanthine..) ubiquinones (e.g.CoQIO), tea catechins (e.g epigallocatechin gallate), coffee extracts containing polyphenols and/or diterpenes (e.g. kawheol and cafestol), ginkgo biloba extracts, grape or grape seed extracts rich in proanthocyanidins, spice extracts (e.g.
- other antioxidants such as vitamin C, vitamin E (tocopherols and tocotrienols), carotenoids (carotenes, lycopene, lutein, zeaxanthine..) ubiquinones (e.g.CoQIO), tea catechins (e.g epigallocatechin gallate), coffee extracts containing poly
- rosemary soy extracts containing isoflavones and related phytoesfrogens and other sources of flavonoids with antioxidant activity, compounds that upregulate cell antioxidant defense (e.g. ursodeoxycholic acid for increased glutathione S-transferase, ursolic acid for increased catalase, ginseng and gingenosides for increase superoxide dismutase and natural sources thereof i.e. herbal medicines).
- soy extracts containing isoflavones and related phytoesfrogens and other sources of flavonoids with antioxidant activity compounds that upregulate cell antioxidant defense (e.g. ursodeoxycholic acid for increased glutathione S-transferase, ursolic acid for increased catalase, ginseng and gingenosides for increase superoxide dismutase and natural sources thereof i.e. herbal medicines).
- the amount of the antioxidant is of at least 0.025 mg per kg of body weight per day, more preferably from 0.025 mg to 250mg per kg of body weight per day.
- the food composition may be a complete and nutritionally balanced food. It can also be a dietary supplement, for example.
- a nutritionally complete pet food can be prepared.
- the nutritionally complete pet food may be in any suitable form; for example in dried form, semi-moist form or wet form; it may be a chilled or shelf stable pet food product.
- These pet foods may be produced as is conventional.
- these pet foods may include any one or more of a carbohydrate source, a protein source and lipid source.
- Any suitable carbohydrate source may be used.
- the carbohydrate source is provided in the form of grains, flours and starches.
- the carbohydrate source may be rice, barley, sorghum, millet, oat, com meal or wheat flour. Simple sugars such as sucrose, glucose and corn syrups may also be used.
- the amount of carbohydrate provided by the carbohydrate source may be selected as desired.
- the pet food may contain up to about 60% by weight of carbohydrate.
- Suitable protein sources may be selected from any suitable animal or vegetable protein source; for example muscular or skeletal meat, meat and bone meal, poultry meal, fish meal, milk proteins, com gluten, wheat gluten, soy flour, soy protein concentrates, soy protein isolates, egg proteins, whey, casein, gluten, and the like.
- the protein source may contain a high quality animal protein.
- the amount of protein provided by the protein source may be selected as desired.
- the pet food may contain about 12% to about 70% by weight of protein on a dry basis.
- the pet food may contain a fat source.
- Any suitable fat source may be used both animal fats and vegetable fats.
- the fat source is an animal fat source such as tallow.
- Vegetable oils such as com oil, sunflower oil, safflower oil, rape seed oil, soy bean oil, olive oil and other oils rich in monounsaturated and polyunsaturated fatty acids, may also be used.
- the fat source may include long chain fatty acids.
- Suitable long chain fatty acids include, gamma linoleic acid, stearidonic acid, arachidonic acid, eicosapentanoic acid, and docosahexanoic acid.
- Fish oils are a suitable source of eicosapentanoic acids and docosahexanoic acid.
- Borage oil, blackcurrent seed oil and evening primrose oil are suitable sources of gamma linoleic acid.
- Rapeseed oil, soybean oil, linseed oil and walnut oil are suitable sources of alpha-linoleic acid.
- Safflower oils, sunflower oils, com oils and soybean oils are suitable sources of linoleic acid.
- Olive oil, rapeseed oil (canola) high oleic sunflower and safflower, peanut oil, rice bran oil are suitable sources of monounsaturated fatty acids.
- the amount of fat provided by the fat source may be selected as desired.
- the pet food may contain about 5% to about 40% by weight of fat on a dry basis.
- the pet food has a relatively reduced amount of fat.
- the pet food may contain other active agents such as long chain fatty acids.
- Suitable long chain fatty acids include alpha-linoleic acid, gamma linoleic acid, linoleic acid, eicosapentanoic acid, and docosahexanoic acid.
- Fish oils are a suitable source of eicosapentanoic acids and docosahexanoic acid.
- Borage oil, blackcurrent seed oil and evening primrose oil are suitable sources of gamma linoleic acid.
- Safflower oils, sunflower oils, com oils and soybean oils are suitable sources of linoleic acid.
- carbohydrate, protein and lipid sources are not critical and will be selected based upon nutritional needs of the animal, palatability considerations, and the type of product produced. Further, various other ingredients, for example, sugar, salt, spices, seasonings, vitamins, minerals, flavoring agents, gums, prebiotics and probiotic micro-organisms may also be incorporated into the pet food as desired.
- the prebiotics may be provided in any suitable form.
- the prebiotic may be provided in the form of plant material, which contains the prebiotic.
- Suitable plant materials include asparagus, artichokes, onions, wheat, yacon or chicory, or residues of these plant materials.
- the prebiotic may be provided as an inulin extract or its hydrolysis products commonly known as fructooligosaccharides, galacto-oligosaccarides, xylo-oligosaccliarides or oligo derivatives of starch. Extracts from chicory are particularly suitable.
- the maximum level of prebiotic in the pet food is preferably about 20% by weight; especially about
- the prebiotic may comprise about 0.1 %> to about 5% by weight of the pet food.
- the chicory may be included to comprise about 0.5% to about 10% by weight of the feed mixture; more preferably about 1% to about 5% by weight.
- the probiotic microorganism may be selected from one or more microorganisms suitable for animal consumption and which is able to improve the microbial balance in the intestine.
- suitable probiotic micro-organisms include yeast such as Saccharomyces, Debar omyces, Candida, Pichia and Torulopsis, moulds such as Aspergillus, Rhizopus, Mucor, and Penicillium and Torulopsis and bacteria such as the genera Bi ⁇ dobacterium, Bacteroides, Clostridium, Fusobacterium, Melissococcus, Propionibacterium, Streptococcus,
- Enterococcus Lactococcus, Staphylococcus, Peptostrepococcus, Bacillus, Pediococcus, Micrococcus, Leuconostoc, Weissella, Aerococcus, Oenococcus and Lactobacillus.
- probiotic micro-organisms are: Saccharomyces cereviseae, Bacillus coagulans, Bacillus licheniformis, Bacillus subtilis, Bi ⁇ dobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Enterococcus faecium, Enterococcus faecalis, Lactobacillus acidophilus, Lactobacillus alimentarius, Lactobacillus casei subsp. casei, Lactobacillus casei Shirota, Lactobacillus curvatus, Lactobacillus delbruckii subsp.
- lactis Lactobacillus farciminus, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus (Lactobacillus GG), Lactobacillus sake, Lactococcus lactis, Micrococcus varians, Pediococcus acidilactici, Pediococcus pentosaceus, Pediococcus acidilactici, Pediococcus halophilus, Streptococcus faecalis, Streptococcus thermophilus, Staphylococcus carnosus, and Staphylococcus xylosus.
- the probiotic micro-organisms may be in powdered, dried form; especially in spore form for micro-organisms which form spores. Further, if desired, the probiotic micro-organism may be encapsulated to further increase the probability of survival; for example in a sugar matrix, fat matrix or polysaccharide matrix.
- the pet food preferably contains about 10 4 to about 10 10 cells of the probiotic micro-organism per gram of the pet food; more preferably about 10 6 to about 10 s cells of the probiotic micro-organism per gram.
- the pet food may contain about 0.5%> to about 20% by weight of the mixture of the probiotic micro-organism; preferably about 1% to about 6% by weight; for example about 3% to about 6% by weight.
- the pet food preferably contains proportionally less fat than pet foods for younger pets.
- the starch sources may include one or more of oat, rice, barley, wheat and com.
- a suitable process is extrusion cooking, although baking and other suitable processes may be used. When extrusion cooked, the dried pet food is usually provided in the form of a kibble. If a prebiotic is used, the prebiotic may be admixed with the other ingredients of the dried pet food prior to processing. A suitable process is described in European patent application No 0850569;. If a probiotic micro-organism is used, the organism is best coated onto or filled into the dried pet food. A suitable process is described in European patent application No 0862863.
- 5,132,137 may be used to produce simulated meat products.
- Other procedures for producing chunk type products may also be used; for example cooking in a steam oven.
- loaf type products may be produced by emulsifying a suitable meat material to produce a meat emulsion, adding a suitable gelling agent, and heating the meat emulsion prior to filling into cans or other containers.
- a food composition for human consumption is prepared.
- This composition may be a nutritional complete formula, a dairy product, a chilled or shelf stable beverage, soup, a dietary supplement, a meal replacement, and a nutritional bar or a confectionery.
- the nutritional formula may comprise a source of protein.
- Dietary proteins are preferably used as a source of protein.
- the dietary proteins may be any suitable dietary protein; for example animal proteins (such as milk proteins, meat proteins and egg proteins); vegetable proteins (such as soy protein, wheat protein, rice protein, and pea protein); mixtures of free a ino acids; or combinations thereof. Milk proteins such as casein, whey proteins and soy proteins are particularly preferred.
- the composition may also contain a source of carbohydrates and a source of fat.
- the fat source preferably provides about 5%o to about 55% > of the energy of the nutritional formula; for example about 20%> to about 50% of the energy.
- the lipids making up the fat source may be any suitable fat or fat mixtures. Vegetable fats are particularly suitable; for example soy oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil, lecithins, and the like. Animal fats such as milk fats may also be added if desired.
- a source of carbohydrate may be added to the nutritional formula. It preferably provides about 40%> to about 80%> of the energy of the nutritional composition. Any suitable carbohydrates may be used, for example sucrose, lactose, glucose, fructose, com syrup solids, and maltodextrins, and mixtures thereof. Dietary fibre may also be added if desired. If used, it preferably comprises up to about 5%> of the energy of the nutritional formula.
- the dietary fibre may be from any suitable origin, including for example soy, pea, oat, pectin, guar gum, gum arabic, and fhictooligosaccharides. Suitable vitamins and minerals may be included in the nutritional formula in an amount to meet the appropriate guidelines.
- One or more food grade emulsifiers may be incorporated into the nutritional formula if desired; for example diacetyl tartaric acid esters of mono- and di- glycerides, lecithin and mono- and di-glycerides. Similarly suitable salts and stabilisers may be included.
- the nutritional formula intended improving or preventing age-related functional deficits is preferably enterally administrable; for example in the form of a powder, a liquid concentrate, or a ready-to-drink beverage. If it is desired to produce a powdered nutritional formula, the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
- a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
- a usual food product may be enriched with the combination according to the present invention.
- the amount of the molecule that stimulates energy metabolism is preferably of at least about 50 ppm by weight and the antioxidant is preferably of at least 10 ppm by weight.
- the food composition according to the present invention can prevent or delay mitochondrial dysfunctions occuring during aging by modulating and/or regulating expression of genes linked to energy metabolism of the cell.
- target genes are those genes involved in (1) energy production: glycolysis, gluconeogenesis, oxidative phosphorylation (respiratory complexes I, II, III, IV, CoQIO, ATPsyntliase, adenine nucleotide translocase), ⁇ -oxidation and tri- carboxylic acid cycle (2) mitochondria biogenesis: membrane components (cardiolipin, PUFAS), protein carriers (ADP/ATP, camitine, phosphate), proteins synthesis (3) proteases (neutral alkaline protease) (4) ROS production and detoxification (Mn-SOD, Glutathione, UCP) (5) modulators of inflammation .
- energy production glycolysis, gluconeogenesis, oxidative phosphorylation (respiratory complexes I, II, III, IV, CoQIO, ATPsyntliase, adenine nucleotide translocase), ⁇ -oxidation and tri- carboxylic acid cycle
- mitochondria biogenesis membrane
- - ATP generation (brain creatine kinase, muscle creatine kinase, mito sarcomeric creatine kinase, ATP synthase, Adenine nucleotide translocase, creatine transporter, tricarboxilate carrier, phosphate transporter, ...),
- thyroid hormone receptor glutamine synthase
- the food composition according to the present invention can also provide multiple benefits by improving age-related functional deficits e.g. in skeletal and cardiac muscle function, vascular function, cognitive function, vision, hearing, olfaction, skin and coat quality, bone and joint health, renal health, gut function, immune function, insulin sensitivity, inflammatory processes, and ultimately increasing longevity in mammals.
- age-related functional deficits e.g. in skeletal and cardiac muscle function, vascular function, cognitive function, vision, hearing, olfaction, skin and coat quality, bone and joint health, renal health, gut function, immune function, insulin sensitivity, inflammatory processes, and ultimately increasing longevity in mammals.
- this invention relates to the use of a combination being able to mimic the effects of caloric restriction on gene expression, which comprises at least one molecule that stimulates energy metabolism of the cell and at least one antioxidant, for the preparation of a composition intended to prevent or restore age-related functional deficits in mammals.
- this invention provides a method to prevent or restore age-related functional deficits in mammals, comprising administering to the mammal, a food composition comprising a combination being able to mimic the effects of caloric restriction on gene expression, said combination containing at least one molecule that stimulates energy metabolism of the cell and at least one antioxidant.
- the said composition may be administered to the mammal as a supplement to the normal diet or as a component of a nutritionally complete food. It is preferred to prepare a nutritionally complete food as described above.
- the amount of the food composition to be consumed by the mammal to obtain a beneficial effect will depend upon its size, its type, and its age. However an amount of said molecule of at least lmg per kg of body weight per day and an amount of the antioxidant of at least 0.025 mg per kg of body weight per day, would usually be adequate.
- Example 1 effect of dietary interventions with antioxidants and activators of mitochondria metabolism in a murine model by gene expression profiling in skeletal muscle.
- mice C57/B16 were obtained from Iffa credo (France) at 9 weeks of age.
- mice Upon arrival mice were housed by groups of 6 animals. After 3 weeks adaptation, mice (12 weeks old) were randomised in 6 groups (A to E) of 12 mice each and housed individually. Dietary intervention was of 3 months; mice had free access to water and were submitted to 12 hours light and dark cycles.
- the control diet (diet A) composed of 18%o proteins (soy and whey), 11% fat (soybean oil), 59% carbohydrates (starch + sucrose) and 10% cellulose was supplemented with either ginkgo biloba extract (diet E), or a cocktail of antioxidants comprising vitamine C, vitamine E, grape seed extract and cysteine (diet C) and/or L-carnitine (diet D and F respectively).
- Diet B fat, starch and sucrose were reduced to provide 67% of the daily calorie consumption of the Ad-lib control group while providing 100%> for proteins, minerals and vitamins.
- Diet A - Control 18% proteins (soy and whey), 11% fat, 59%o carbohydrates, 5% cellulose.
- Diet B - Caloric restriction 18% proteins (soy and whey), 7.7% fat, 32.5% carbohydrates, 5%> cellulose
- Diet C - Cocktail of antioxidants Diet A + 0.19% vit C, 0.03% vit E, 0.075% grape seed extract, 0.4% cysteine.
- Diet D Diet A + 0.3% L- camitine + cocktail of antioxidants of diet C.
- Diet E Diet A + 0.0375% Ginkgo biloba extract (Linnea)
- RNAlatter (gastrocnemius) were immersed in RNAlatter (Ambion) and frozen at -80°C until use.
- muscles were homogenized with ceramic beads (FastPrep, Q-Biogene) and the RNA extracted with Totally RNA kit (Ambion). The quality of the RNA was checked by Agilent technology. RNA pools from four mice each were created and hybridized to Affymetrix Murine U74Av2 high-density oligonucleotide microarrays.
- Example 2 Dry pet food A feed mixture is made up of about 58% by weight of com, about 5.5% by weight of com gluten, about 22% by weight of chicken meal, 2,5% dried chicory, 1% camitine, and 1% creatine for stimulation of energy metabolism, 0.1% Vit C, vit E
- the fed mixture is fed into a preconditioner and moistened.
- the moistened feed is then fed into an extruder-cooker and gelatinised.
- the gelatinised matrix leaving the extruder is forced through a die and extruded.
- the extrudate is cut into pieces suitable for feeding to dogs, dried at about 110°C for about 20 minutes, and cooled to form pellets.
- This dry dog food is able to improve or restore the age-related deficits in dogs.
- a feed mixture is prepared as in example 1, using 2% camitine for stimulation of energy metabolism and 0.05% ginkgo biloba extract as antioxidant. Then, the fed mixture is processed as in example 1.
- the dry dog food is also particularly intended to improve or restore the age-related deficits in dogs.
- a mixture is prepared from 73 %> of poultry carcass, pig lungs and beef liver
- This mixture is emulsified at 12°C and extruded in the form of a pudding which is then cooked at a temperature of 90°C. It is cooled to 30°C and cut in chunks. 45 % of these chunks are mixed with 55 % of a sauce prepared from 98 % of water, 1 % of dye, and 1 % of guar gum. Tinplate cans are filled and sterilized at
- a mixture is prepared from 56% of poultry carcass, pig lungs and pig liver (ground), 13% of fish, 16% of wheat flour, 2% of plasma, 10.8% of water, 2.2% of dyes, 1% of semi refined kappa carrageenan, inorganic salts and 9% oil rich in monounsaturated fatty acids (olive oil) and 1 %> creatine for stimulation of energy metabolism and 1 % taurine as antioxidant.
- This mixture is emulsified at 12°C and extruded in the form of a pudding which is then cooked at a temperature of 90°C. It is cooled to 30°C and cut in chunks.
- a nutritional composition is prepared, and which contains for 100 g of powder : 15 % of protein hydrolysate, 25 % of fats, 55 % carbohydrates (including maltodextrin 37 %, starch 6 %, sucrose 12 %), traces of vitamins and oligoelements to meet daily requirements, 2 % minerals and 3 %> moisture and 2% pyruvate for stimulation of energy metabolism and 1% carnosine or carnosine precursor as antioxidant.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02750544A EP1372412A2 (en) | 2001-03-09 | 2002-03-07 | Composition improving age-related physiological deficits and increasing longevity |
| BR0207948-8A BR0207948A (en) | 2001-03-09 | 2002-03-07 | Composition that improves age-related physiological deficits and increases longevity |
| CA002439078A CA2439078C (en) | 2001-03-09 | 2002-03-07 | Composition improving age-related physiological deficits and increasing longevity |
| EA200300994A EA006429B1 (en) | 2001-03-09 | 2002-03-07 | Composition for preventing or restoring age-related functional deficits in mammals and method for use |
| JP2002570843A JP2004519241A (en) | 2001-03-09 | 2002-03-07 | Composition that improves physiological disorders associated with aging and extends lifespan |
| MXPA03007802A MXPA03007802A (en) | 2001-03-09 | 2002-03-07 | Composition improving age-related physiological deficits and increasing longevity. |
| IL15736702A IL157367A0 (en) | 2001-03-09 | 2002-03-07 | Composition improving age-related physiological deficits and increasing longevity |
| PL02363426A PL363426A1 (en) | 2001-03-09 | 2002-03-07 | Composition improving age-related physiological deficits and increasing longevity |
| KR10-2003-7011809A KR20030088453A (en) | 2001-03-09 | 2002-03-07 | Composition improving age-related physiological deficits and increasing longevity |
| IL157367A IL157367A (en) | 2001-03-09 | 2003-08-12 | Composition for improving age-related physiological deficits and for increasing longevity |
| US10/656,955 US20040047896A1 (en) | 2001-03-09 | 2003-09-05 | Composition for improving age-related physiological deficits and increasing longevity |
| NO20033941A NO20033941D0 (en) | 2001-03-09 | 2003-09-05 | Composition that improves age-related physiological deficiencies that prolong life |
| US11/011,223 US20050100617A1 (en) | 2001-03-09 | 2004-12-13 | Method for improving age-related physiological deficits and increasing longevity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01200871.0 | 2001-03-09 | ||
| EP01200871 | 2001-03-09 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/656,955 Continuation US20040047896A1 (en) | 2001-03-09 | 2003-09-05 | Composition for improving age-related physiological deficits and increasing longevity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002071874A2 true WO2002071874A2 (en) | 2002-09-19 |
| WO2002071874A3 WO2002071874A3 (en) | 2003-01-09 |
Family
ID=8179979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2002/002862 Ceased WO2002071874A2 (en) | 2001-03-09 | 2002-03-07 | Composition improving age-related physiological deficits and increasing longevity |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040047896A1 (en) |
| EP (1) | EP1372412A2 (en) |
| JP (1) | JP2004519241A (en) |
| KR (1) | KR20030088453A (en) |
| CN (1) | CN1638650A (en) |
| AR (1) | AR032974A1 (en) |
| AU (1) | AU2008201296A1 (en) |
| BR (1) | BR0207948A (en) |
| CA (1) | CA2439078C (en) |
| EA (1) | EA006429B1 (en) |
| IL (2) | IL157367A0 (en) |
| MX (1) | MXPA03007802A (en) |
| NO (1) | NO20033941D0 (en) |
| PE (1) | PE20020987A1 (en) |
| PL (1) | PL363426A1 (en) |
| WO (1) | WO2002071874A2 (en) |
| ZA (1) | ZA200307865B (en) |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107498A1 (en) * | 2004-05-10 | 2005-11-17 | Toyo Shinyaku Co., Ltd. | Food containing polyphenol |
| WO2005123058A1 (en) * | 2004-06-15 | 2005-12-29 | Osaka Prefectural Government | Antiaging agent |
| WO2004081537A3 (en) * | 2003-03-12 | 2006-03-23 | Univ California | Methods of evaluating caloric restriction and identifying caloric restriction mimetics |
| EP1645276A1 (en) * | 2004-10-08 | 2006-04-12 | Wageningen Centre for Food Sciences | Treatment of neurodegenerative disorders |
| WO2007029730A1 (en) * | 2005-09-06 | 2007-03-15 | Meiji Dairies Corporation | Amino acid composition for prevention or treatment of senile anemia |
| JP2007509955A (en) * | 2003-10-27 | 2007-04-19 | ボード・オブ・トラスティーズ・オブ・サザン・イリノイ・ユニバーシティ | Therapeutic use of methionine for the prevention and treatment of mucositis |
| JP2007519678A (en) * | 2004-01-28 | 2007-07-19 | ネステク ソシエテ アノニム | Nutritional composition for improving skin condition and preventing skin diseases |
| DE102007030495A1 (en) * | 2007-06-30 | 2009-01-15 | Alzchem Trostberg Gmbh | Use of creatine containing preparation e.g. for improving memory, retentivity, long-term memory and for preventing mental fatigue condition, comprising e.g. Ginkgo biloba, ginseng and niacin |
| EP2123171A1 (en) * | 2008-05-20 | 2009-11-25 | Otto Thannesberger | Feed mixture |
| WO2010051120A1 (en) * | 2008-10-30 | 2010-05-06 | The Iams Company | Pet food composition comprising an antioxidant component |
| EP1952701A3 (en) * | 2004-09-21 | 2011-06-08 | Nestec S.A. | Improving longevity and the condition of elderly cats |
| US20120040929A1 (en) * | 2003-11-21 | 2012-02-16 | Nestec S.A. | Food composition comprising glucosamine |
| AU2007211625B2 (en) * | 2006-02-01 | 2012-08-23 | Nestec S.A. | Nutritional system and methods for increasing longevity |
| EP2532355A1 (en) * | 2011-06-06 | 2012-12-12 | Nestec S.A. | Chicory for prevention and treatment of neurodegeneration |
| EP1492415B1 (en) * | 2002-04-05 | 2013-01-09 | Nestec S.A. | Method of improving absorption of vitamin e by a pet animal |
| US8535708B2 (en) | 2004-12-29 | 2013-09-17 | Hill's Pet Nutrition, Inc. | Methods for inhibiting a decline in learning and/or memory in animals |
| US8592478B2 (en) | 2000-10-31 | 2013-11-26 | Hill's Pet Nutrition, Inc. | Antioxidant-containing food composition |
| US8617587B2 (en) | 2002-03-11 | 2013-12-31 | Novartis Ag | Tasted masked veterinary solid compositions |
| US20150164833A1 (en) * | 2013-12-17 | 2015-06-18 | Mead Johnson Nutrition Company | Nutritional composition containing a neurologic component of ursolic acid and uses thereof |
| WO2018152160A1 (en) * | 2017-02-14 | 2018-08-23 | University Of Southern California | Fasting mimicking diet |
| EP1383514B2 (en) † | 2001-03-22 | 2018-12-19 | Societe Des Produits Nestle S.A. | Use of a composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters |
| IT201800000890A1 (en) * | 2018-01-15 | 2019-07-15 | Sirt500 Sagl | NUTRACEUTICAL COMPOSITION FOR THE ACTIVATION OF SYRTUINS WITH ANTI-AGING / REVERSE-AGING EFFECT |
| EP2023945B1 (en) * | 2006-06-08 | 2019-08-07 | IAMS Europe B.V. | Composition for improving eye health |
| RU2743166C2 (en) * | 2016-11-04 | 2021-02-15 | Чентро Дерматолоджико С.Р.Л. | Cosmetic method |
| US11077165B2 (en) | 2004-11-09 | 2021-08-03 | Hills Pet Nutrition, Inc. | Use of antioxidants for gene modulation |
| US11767314B2 (en) | 2018-11-02 | 2023-09-26 | Conopco, Inc. | Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same |
| US20240148026A1 (en) * | 2021-03-17 | 2024-05-09 | Hyo Gyoung Yu | Liquid-phase, supplementary feed composition containing coenzyme q10 |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563522B2 (en) * | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
| US8669282B2 (en) | 2000-10-31 | 2014-03-11 | Hill's Pet Nutrition, Inc. | Companion animal compositions including lipoic acid and methods of use thereof |
| US7666459B2 (en) * | 2001-09-12 | 2010-02-23 | The Procter & Gamble Company | Pet food compositions |
| CA2498199C (en) * | 2002-09-09 | 2012-01-17 | Nestec S.A. | Orally administrable composition for improving hair and coat quality |
| FI20022175A0 (en) * | 2002-12-10 | 2002-12-10 | Labmax Oy | Food oil product and its use |
| US7332178B2 (en) * | 2003-04-25 | 2008-02-19 | Abbott Laboratories | Stable nutritional powder containing ascorbyl palmitate |
| US8192733B2 (en) * | 2003-08-29 | 2012-06-05 | Cobb & Associates | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
| US7759105B2 (en) * | 2003-08-29 | 2010-07-20 | Cobb & Company, Llp | Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions |
| US7749509B2 (en) * | 2003-08-29 | 2010-07-06 | Cobb And Company, Llp | Treatment of autism using probiotic composition |
| US7731976B2 (en) * | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| ES2809302T3 (en) | 2004-01-22 | 2021-03-03 | Univ Miami | Coenzyme Q10 formulations to treat solid tumors by intravenous administration |
| US20090252834A1 (en) * | 2004-05-10 | 2009-10-08 | Michael Griffin Hayek | Compositions comprising glucose anti-metabolites |
| US20050266051A1 (en) * | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
| AU2012211482B2 (en) * | 2004-05-27 | 2014-08-21 | Mars, Incorporated | Pet food compositions and methods |
| DE102004026706A1 (en) * | 2004-05-28 | 2005-12-15 | Merck Patent Gmbh | Oral dosage form containing probiotic bacteria |
| JP2006014730A (en) * | 2004-05-31 | 2006-01-19 | Toyo Shinyaku:Kk | Food product |
| WO2006058278A2 (en) * | 2004-11-24 | 2006-06-01 | Hill's Pet Nutrition, Inc. | Methods for improving liver clearance of xenobiotic substances in an animal |
| US20090176864A1 (en) * | 2004-11-24 | 2009-07-09 | Hill's Pet Nutrition, Inc. | Methods For Improving Hepatic and Immune Function In An Animal |
| CN101068480A (en) * | 2004-12-03 | 2007-11-07 | 爱科来株式会社 | Water-soluble dry food |
| JP2008524123A (en) * | 2004-12-21 | 2008-07-10 | クリティカル ケア コネクションズ インク | Therapeutic nutritional compositions or combinations and methods of their use |
| US8647660B2 (en) | 2004-12-29 | 2014-02-11 | Hill's Pet Nutrition, Inc. | Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health |
| US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| US8148325B2 (en) * | 2004-12-30 | 2012-04-03 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| US20070118295A1 (en) * | 2005-03-02 | 2007-05-24 | Al-Murrani Samer Waleed Khedhe | Methods and Systems for Designing Animal Food Compositions |
| US7198834B2 (en) * | 2005-03-22 | 2007-04-03 | Hewlett-Packard Development Company, L.P. | Imaging media including interference layer for generating human-readable marking on optical media |
| BRPI0610731A2 (en) * | 2005-04-19 | 2012-10-30 | Hills Pet Nutrition Inc | composition, method for preventing or treating kidney disease, kit for administering a kidney disease prevention or treatment composition to the patient, method for promoting kidney health, means for communicating information about or instructions for mixing and administering one or more of the compositions, components of the composition, food compositions, food ingredients, and renal drugs, and for the use of renal diagnostic devices of the present invention, and use of a composition. |
| ATE512211T1 (en) | 2005-05-31 | 2011-06-15 | Iams Company | FELINE PROBIOTIC LACTOBACILLI |
| AU2006253007B2 (en) | 2005-05-31 | 2012-12-20 | Alimentary Health Ltd | Feline probiotic Bifidobacteria |
| US20090209647A1 (en) * | 2005-06-14 | 2009-08-20 | Nestec S.A. | Nutritional method |
| EP1906912B1 (en) | 2005-07-14 | 2012-08-15 | Hill's Pet Nutrition, Inc. | Method for prolonging the life of animals |
| US8492432B2 (en) * | 2005-08-17 | 2013-07-23 | Hill's Pet Nutrition, Inc. | Methods for the treatment of kidney disease |
| US20090148426A1 (en) | 2005-09-22 | 2009-06-11 | Kaneka Corporation | Composition for life extension and method of extending the life |
| US8246946B2 (en) * | 2005-09-27 | 2012-08-21 | Cobb & Associates | Treatment of bipolar disorder utilizing anti-fungal compositions |
| US20070092577A1 (en) * | 2005-10-03 | 2007-04-26 | University Of Tennessee Research Foundation | Dietary calcium for reducing the production of reactive oxygen species |
| CA2642431A1 (en) * | 2006-02-15 | 2007-08-23 | Nestec S.A. | Use of bifidobacterium longum for the prevention and treatment of inflammation |
| US7960605B2 (en) | 2006-03-17 | 2011-06-14 | BioMaker Pharmaceuticals, Inc. | Methods for testing for caloric restriction (CR) mimetics |
| JP5264702B2 (en) * | 2006-03-29 | 2013-08-14 | ネステク ソシエテ アノニム | Nutritional supplements containing probiotics |
| WO2008007245A2 (en) * | 2006-06-07 | 2008-01-17 | The Iams Company | Natural preservatives for preservation of perishable products |
| JP5281234B2 (en) * | 2006-06-27 | 2013-09-04 | ポーラ化成工業株式会社 | Orally administered composition for the improvement and prevention of fatigued eyes due to ciliary overtension |
| EP2036552B1 (en) | 2006-07-05 | 2018-08-08 | Kao Corporation | Senescence inhibitor |
| JP2008013473A (en) * | 2006-07-05 | 2008-01-24 | Kao Corp | Muscle function inhibitor |
| EP2124966B1 (en) | 2007-02-01 | 2015-09-09 | IAMS Europe B.V. | Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts |
| US20090038024A1 (en) * | 2007-06-19 | 2009-02-05 | The Regents Of The University Of California | Cap/sorbs1 and diabetes |
| EP2022502A1 (en) * | 2007-08-10 | 2009-02-11 | Nestec S.A. | Lactobacillus rhamnosus and weight control |
| US20100129467A9 (en) | 2007-08-31 | 2010-05-27 | Albritton Iv Ford D | Nutritional supplement |
| ES2716474T3 (en) | 2007-10-26 | 2019-06-12 | Avivagen Inc | Compositions and methods to improve the immune response |
| JPWO2009066562A1 (en) * | 2007-11-20 | 2011-04-07 | 明治乳業株式会社 | Erythrocyte stem cell differentiation promoter and / or proliferation promoter, and use of methionine for preventing or treating senile anemia and a composition containing methionine |
| AU2009210728B2 (en) * | 2008-02-07 | 2014-06-19 | Société des Produits Nestlé S.A. | Compositions and methods for influencing recovery from strenuous physical activity |
| AU2009233785B2 (en) | 2008-04-11 | 2015-08-20 | Berg Llc | Methods and use of inducing apoptosis in cancer cells |
| US9771199B2 (en) * | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US9232813B2 (en) * | 2008-07-07 | 2016-01-12 | The Iams Company | Probiotic supplement, process for making, and packaging |
| CN102170792A (en) * | 2008-07-18 | 2011-08-31 | 希尔氏宠物营养品公司 | Method for enhancing the quality of life of a senior animal |
| AU2009282482B2 (en) * | 2008-08-15 | 2015-11-26 | Société des Produits Nestlé S.A. | Methods for enhancing energy metabolism |
| US20100112181A1 (en) * | 2008-10-30 | 2010-05-06 | Matthew Joel Taylor | Recovery of Antioxidants from Decaffeination Process |
| EP2216034A1 (en) * | 2009-02-10 | 2010-08-11 | Nestec S.A. | Lactobacillus helveticus CNCM I-4095 and weight control |
| EP2216035A1 (en) * | 2009-02-10 | 2010-08-11 | Nestec S.A. | Lactobacillus rhamnosus CNCM I-4096 and weight control |
| WO2010124391A1 (en) * | 2009-04-30 | 2010-11-04 | Chemaphor Inc. | Methods and compositions for improving the health of animals |
| AU2010247800A1 (en) | 2009-05-11 | 2011-12-15 | Berg Llc | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| US8691303B2 (en) * | 2009-07-31 | 2014-04-08 | The Iams Company | Dusted animal food |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| US9210945B2 (en) * | 2009-07-31 | 2015-12-15 | The Iams Company | Animal food having low water activity |
| US20110027417A1 (en) * | 2009-07-31 | 2011-02-03 | Patrick Joseph Corrigan | Process for Dusting Animal Food |
| US9173423B2 (en) * | 2009-07-31 | 2015-11-03 | The Iams Company | Animal food kibble with electrostatically adhered dusting |
| CN102695428A (en) * | 2010-01-06 | 2012-09-26 | 雀巢产品技术援助有限公司 | Dietary regimens useful for mimicking caloric restriction |
| EP2444083A1 (en) * | 2010-10-21 | 2012-04-25 | Nestec S.A. | Cysteine and food intake |
| CN103209596A (en) * | 2010-11-11 | 2013-07-17 | 雀巢产品技术援助有限公司 | Frozen confections containing probiotic micro-organisms |
| EP2452576A1 (en) * | 2010-11-11 | 2012-05-16 | Nestec S.A. | Extruded non-replicating probiotic micro-organisms and their health benefits |
| ES2708924T3 (en) * | 2010-12-31 | 2019-04-12 | Abbott Lab | Procedures for the use of oligosaccharides in human milk to improve respiratory health of the respiratory tract |
| CA2832324C (en) | 2011-04-04 | 2022-03-15 | Berg Llc | Methods of treating central nervous system tumors |
| CN107217051A (en) * | 2011-06-15 | 2017-09-29 | Nse产品公司 | Recognize heat limit markers thing and heat limitation analogies |
| US8623924B2 (en) | 2011-07-15 | 2014-01-07 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
| SI2753311T1 (en) * | 2011-09-09 | 2020-12-31 | Kemin Industries, Inc. | Antioxidant formulations |
| FR2982460B1 (en) * | 2011-11-14 | 2016-08-05 | Virbac Sa | ORAL ADMINISTRATION PRODUCTS COMPRISING PUNICA GRANATUM GRANITE EXTRACTS FOR ANIMAL PET AND ITS APPLICATIONS |
| US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
| WO2014027864A1 (en) * | 2012-08-16 | 2014-02-20 | 경희대학교 산학협력단 | Lactic acid bacteria capable of preventing and/or treating senescence and dementia |
| CN102783568B (en) * | 2012-08-29 | 2014-05-14 | 山东中医药大学 | Feed additive |
| MX2015006023A (en) | 2012-11-13 | 2016-03-31 | Nusirt Sciences Inc | COMPOSITIONS AND METHODS TO INCREASE ENERGETIC METABOLISM. |
| AU2014225786B2 (en) | 2013-03-08 | 2017-10-12 | Axiom Foods, Inc. | Rice protein supplements |
| US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
| CN105228627B (en) | 2013-03-15 | 2018-07-13 | 纽斯尔特科学公司 | Leucine and niacin reduce lipid level |
| WO2014149280A1 (en) * | 2013-03-15 | 2014-09-25 | Nusirt Sciences, Inc. | Treatment of pets with sirtuin activators |
| SG10201903112WA (en) | 2013-04-08 | 2019-05-30 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
| KR102370843B1 (en) | 2013-09-04 | 2022-03-04 | 버그 엘엘씨 | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
| CN103461674B (en) * | 2013-09-23 | 2014-12-31 | 大连圣弘医药有限公司 | Formula of pet functional food capable of effectively activating pet joints and preparation method of food |
| EP3110507B1 (en) | 2014-02-27 | 2020-11-18 | NuSirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
| US20150335688A1 (en) * | 2014-05-21 | 2015-11-26 | Medlab Ip Pty Ltd | Probiotic combinations and uses thereof |
| CA2975219C (en) | 2015-02-16 | 2022-02-22 | Mars, Incorporated | Interlocking kibble |
| CN107529789A (en) | 2015-04-28 | 2018-01-02 | 马斯公司 | Method of preparing sterilized wet pet food |
| WO2017087576A1 (en) | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| EP3434783A4 (en) | 2016-03-26 | 2019-11-06 | Kawasaki Gakuen Educational Foundation | BIOMARKER MITOCHONDRIAL REFLECTING AGING |
| USD805728S1 (en) | 2016-09-06 | 2017-12-26 | Mars, Incorporated | Food product |
| USD806351S1 (en) | 2016-09-06 | 2018-01-02 | Mars, Incorporated | Food product |
| GB201701417D0 (en) | 2017-01-27 | 2017-03-15 | Mars Inc | Pet food |
| WO2018209131A1 (en) | 2017-05-12 | 2018-11-15 | Axiom Foods, Inc. | Rice products and systems and methods for making thereof |
| CN109045059A (en) * | 2018-08-01 | 2018-12-21 | 泓博元生命科技(深圳)有限公司 | A kind of anti-aging, the composition for improving male's energy, preparation and the preparation method and application thereof |
| US12083152B2 (en) | 2018-09-26 | 2024-09-10 | Meiji Co., Ltd. | Agent for improving mitochondrial function |
| CA3119100C (en) * | 2018-11-09 | 2024-06-04 | Valter D. Longo | Nutrition bar for intermittent fasting-mimicking |
| EP3996668B1 (en) * | 2019-07-12 | 2024-10-16 | Unilever Global IP Limited | Topical compositions and methods of using same against mitochondrial fragmentation |
| CN112079911B (en) * | 2020-09-04 | 2022-04-08 | 扬州大学 | Key gene GbMYB6 for promoting synthesis of ginkgo flavonoids, and protein, vector and application of key gene GbMYB6 for expression |
| CN112080507B (en) * | 2020-09-04 | 2022-04-08 | 扬州大学 | Key gene GbMYB4 for regulating and controlling ginkgo flavonoid synthesis, protein expressed by gene GbMYB4, vector and application of gene GbMYB4 |
| WO2022190120A1 (en) * | 2021-03-12 | 2022-09-15 | Thinking Forks Consulting Private Limited | Nutritional supplement composition for geriatric population and a method of producing the composition |
| CN116262121A (en) * | 2021-12-15 | 2023-06-16 | 南湖实验室 | Use of tauroursodeoxycholic acid and its sodium salt in anti-aging and/or life extension |
| KR102779455B1 (en) * | 2024-09-03 | 2025-03-13 | 이대훈 | Composition for improving eyes health and preventing tear pigmentation for pets and nutritional supplements for companion animals using same |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156769B (en) * | 1978-05-25 | 1987-02-04 | Sigma Tau Ind Farmaceuti | THERAPEUTIC APPLICATION OF CARNITINE AND OTHER ACIL DERIVATIVES OF CARNITINE |
| US4330557A (en) * | 1979-05-21 | 1982-05-18 | Claudio Cavazza | Acyl-carnitine and use thereof in parenteral administration of triglycerides |
| US4921877A (en) * | 1986-10-27 | 1990-05-01 | Abbott Laboratories | Liquid nutritional formula for glucose intolerance |
| US4883672A (en) * | 1988-04-29 | 1989-11-28 | Shug Austin L | Method for preventing diet induced carnitine deficiency in domesticated dogs and cats |
| US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
| FI104465B (en) * | 1995-06-14 | 2000-02-15 | Valio Oy | Protein hydrolyzates for the treatment and prevention of allergies and their preparation and use |
| US6022867A (en) * | 1996-11-27 | 2000-02-08 | Showa Denko Kabushiki Kaisha | Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals |
| DK0969744T3 (en) * | 1997-03-27 | 2003-06-23 | Khursheed N Jeejeebhoy | Supplements for enhancements of cellular energy |
| US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| US5973004A (en) * | 1997-04-04 | 1999-10-26 | Howard; James R. | L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism |
| FR2761887B1 (en) * | 1997-04-11 | 1999-06-18 | Roland Asmar | MEDICATION FOR MULTIFACTORIAL PREVENTION OF CARDIOVASCULAR DISEASES |
| US5916912A (en) * | 1997-06-16 | 1999-06-29 | The Regents Of The University Of California | Dietary composition for enhancing metabolism and alleviating oxidative stress |
| US5922766A (en) * | 1997-07-02 | 1999-07-13 | Acosta; Phyllis J. B. | Palatable elemental medical food |
| DE19806890A1 (en) * | 1998-02-19 | 1999-08-26 | Beiersdorf Ag | Combination of (acyl) carnitine and oxidant for use in skin care, effective e.g. against light-induced damage and inflammation |
| US5926849A (en) * | 1998-03-31 | 1999-07-27 | Boyle; Kevin J. | Baseball cap with a channeled, laminated inside head band |
| US5932258A (en) * | 1998-04-06 | 1999-08-03 | The Iams Company | Composition and process for improving glucose metabolism in companion animals |
| IT1299191B1 (en) * | 1998-06-23 | 2000-02-29 | Sigma Tau Healthscience Spa | COMPOSITION TO PREVENT AND TREAT OSTEOPOROSIS AND ALTERATIONS RELATED TO MENOPAUSE |
| IT1302307B1 (en) * | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | COMPOSITION WITH ANTIOXIDANT ACTIVITY AND FOR IMPROVING THE METABOLIC USE OF GLUCOSE, INCLUDING ACETYL |
| IT1304406B1 (en) * | 1998-10-21 | 2001-03-19 | Danital Italia S R L | PREPARATION FOR THE VEHICULATION OF ACTIVE INGREDIENTS BASED ON POLYUNSATURATED ACIDIGIDS OF THE OMEGA GROUP 3. |
| US6562869B1 (en) * | 1999-09-23 | 2003-05-13 | Juvenon, Inc. | Nutritional supplement for increased energy and stamina |
| IT1306722B1 (en) * | 1999-10-08 | 2001-10-02 | Sigma Tau Healthscience Spa | COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CIRCULATORY DYSFUNCTIONS, INCLUDING L-CARNITINE DERIVATIVES AND EXTRACTS OF |
| CA2389623A1 (en) * | 1999-11-03 | 2001-05-10 | Juvenon, Inc. | Method of treating benign forgetfulness |
| US20020146400A1 (en) * | 2000-01-07 | 2002-10-10 | Cincotta Anthony H. | Composition for reducing plasma triglycerides, platelet aggregation, and oxidative capacity |
| JP2003529347A (en) * | 2000-01-25 | 2003-10-07 | ジュヴェノン インコーポレイテッド | Nutrition supplements for aged pets |
| US6277842B1 (en) * | 2000-10-17 | 2001-08-21 | James Alexander Carthron | Dietary supplemental method for fat and weight reduction |
| CA2498199C (en) * | 2002-09-09 | 2012-01-17 | Nestec S.A. | Orally administrable composition for improving hair and coat quality |
| JP2007519678A (en) * | 2004-01-28 | 2007-07-19 | ネステク ソシエテ アノニム | Nutritional composition for improving skin condition and preventing skin diseases |
-
2002
- 2002-03-07 PL PL02363426A patent/PL363426A1/en not_active Application Discontinuation
- 2002-03-07 KR KR10-2003-7011809A patent/KR20030088453A/en not_active Ceased
- 2002-03-07 IL IL15736702A patent/IL157367A0/en active IP Right Grant
- 2002-03-07 EA EA200300994A patent/EA006429B1/en not_active IP Right Cessation
- 2002-03-07 MX MXPA03007802A patent/MXPA03007802A/en not_active Application Discontinuation
- 2002-03-07 WO PCT/EP2002/002862 patent/WO2002071874A2/en not_active Ceased
- 2002-03-07 CA CA002439078A patent/CA2439078C/en not_active Expired - Fee Related
- 2002-03-07 BR BR0207948-8A patent/BR0207948A/en not_active IP Right Cessation
- 2002-03-07 JP JP2002570843A patent/JP2004519241A/en active Pending
- 2002-03-07 CN CNA028062175A patent/CN1638650A/en active Pending
- 2002-03-07 EP EP02750544A patent/EP1372412A2/en not_active Ceased
- 2002-03-08 PE PE2002000185A patent/PE20020987A1/en not_active Application Discontinuation
- 2002-03-08 AR ARP020100850A patent/AR032974A1/en unknown
-
2003
- 2003-08-12 IL IL157367A patent/IL157367A/en not_active IP Right Cessation
- 2003-09-05 NO NO20033941A patent/NO20033941D0/en not_active Application Discontinuation
- 2003-09-05 US US10/656,955 patent/US20040047896A1/en not_active Abandoned
- 2003-10-08 ZA ZA200307865A patent/ZA200307865B/en unknown
-
2004
- 2004-12-13 US US11/011,223 patent/US20050100617A1/en not_active Abandoned
-
2008
- 2008-03-20 AU AU2008201296A patent/AU2008201296A1/en not_active Abandoned
Cited By (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8592478B2 (en) | 2000-10-31 | 2013-11-26 | Hill's Pet Nutrition, Inc. | Antioxidant-containing food composition |
| EP1383514B2 (en) † | 2001-03-22 | 2018-12-19 | Societe Des Produits Nestle S.A. | Use of a composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters |
| US8617587B2 (en) | 2002-03-11 | 2013-12-31 | Novartis Ag | Tasted masked veterinary solid compositions |
| US8475834B2 (en) | 2002-04-05 | 2013-07-02 | Nestec S.A. | Method of improving absorption of vitamin E by a pet animal |
| EP1492415B1 (en) * | 2002-04-05 | 2013-01-09 | Nestec S.A. | Method of improving absorption of vitamin e by a pet animal |
| EP1601949A4 (en) * | 2003-03-12 | 2007-07-18 | Univ California | METHODS FOR CALORIALLY RESTRICTING EVALUATION AND IDENTIFICATION OF CALIMATE RESTRICTION MIMETIC AGENTS |
| WO2004081537A3 (en) * | 2003-03-12 | 2006-03-23 | Univ California | Methods of evaluating caloric restriction and identifying caloric restriction mimetics |
| JP2007509955A (en) * | 2003-10-27 | 2007-04-19 | ボード・オブ・トラスティーズ・オブ・サザン・イリノイ・ユニバーシティ | Therapeutic use of methionine for the prevention and treatment of mucositis |
| JP4884974B2 (en) * | 2003-10-27 | 2012-02-29 | ボード・オブ・トラスティーズ・オブ・サザン・イリノイ・ユニバーシティ | Therapeutic use of methionine for the prevention and treatment of mucositis |
| US20120040929A1 (en) * | 2003-11-21 | 2012-02-16 | Nestec S.A. | Food composition comprising glucosamine |
| US9393253B2 (en) * | 2003-11-21 | 2016-07-19 | Nestec S.A. | Food composition comprising glucosamine |
| JP2007519678A (en) * | 2004-01-28 | 2007-07-19 | ネステク ソシエテ アノニム | Nutritional composition for improving skin condition and preventing skin diseases |
| WO2005107498A1 (en) * | 2004-05-10 | 2005-11-17 | Toyo Shinyaku Co., Ltd. | Food containing polyphenol |
| JPWO2005123058A1 (en) * | 2004-06-15 | 2008-04-10 | 大阪府 | Anti-aging agent |
| WO2005123058A1 (en) * | 2004-06-15 | 2005-12-29 | Osaka Prefectural Government | Antiaging agent |
| EP1952701A3 (en) * | 2004-09-21 | 2011-06-08 | Nestec S.A. | Improving longevity and the condition of elderly cats |
| EP1645276A1 (en) * | 2004-10-08 | 2006-04-12 | Wageningen Centre for Food Sciences | Treatment of neurodegenerative disorders |
| US11077165B2 (en) | 2004-11-09 | 2021-08-03 | Hills Pet Nutrition, Inc. | Use of antioxidants for gene modulation |
| US8535708B2 (en) | 2004-12-29 | 2013-09-17 | Hill's Pet Nutrition, Inc. | Methods for inhibiting a decline in learning and/or memory in animals |
| WO2007029730A1 (en) * | 2005-09-06 | 2007-03-15 | Meiji Dairies Corporation | Amino acid composition for prevention or treatment of senile anemia |
| JP5220415B2 (en) * | 2005-09-06 | 2013-06-26 | 株式会社明治 | Amino acid composition for preventing or treating senile anemia |
| AU2007211625B2 (en) * | 2006-02-01 | 2012-08-23 | Nestec S.A. | Nutritional system and methods for increasing longevity |
| EP1978984B1 (en) | 2006-02-01 | 2015-06-10 | Nestec S.A. | Nutritional system and methods for increasing longevity |
| EP2023945B1 (en) * | 2006-06-08 | 2019-08-07 | IAMS Europe B.V. | Composition for improving eye health |
| DE102007030495A1 (en) * | 2007-06-30 | 2009-01-15 | Alzchem Trostberg Gmbh | Use of creatine containing preparation e.g. for improving memory, retentivity, long-term memory and for preventing mental fatigue condition, comprising e.g. Ginkgo biloba, ginseng and niacin |
| EP2123171A1 (en) * | 2008-05-20 | 2009-11-25 | Otto Thannesberger | Feed mixture |
| WO2010051120A1 (en) * | 2008-10-30 | 2010-05-06 | The Iams Company | Pet food composition comprising an antioxidant component |
| EP3115046A1 (en) * | 2008-10-30 | 2017-01-11 | IAMS Europe B.V. | Pet food composition comprising an antioxidant component |
| EP2532355A1 (en) * | 2011-06-06 | 2012-12-12 | Nestec S.A. | Chicory for prevention and treatment of neurodegeneration |
| WO2012168245A1 (en) * | 2011-06-06 | 2012-12-13 | Nestec S.A. | Chicory for prevention and treatment of neurodegeneration |
| US20150164833A1 (en) * | 2013-12-17 | 2015-06-18 | Mead Johnson Nutrition Company | Nutritional composition containing a neurologic component of ursolic acid and uses thereof |
| RU2743166C2 (en) * | 2016-11-04 | 2021-02-15 | Чентро Дерматолоджико С.Р.Л. | Cosmetic method |
| WO2018152160A1 (en) * | 2017-02-14 | 2018-08-23 | University Of Southern California | Fasting mimicking diet |
| US11284640B2 (en) | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
| IT201800000890A1 (en) * | 2018-01-15 | 2019-07-15 | Sirt500 Sagl | NUTRACEUTICAL COMPOSITION FOR THE ACTIVATION OF SYRTUINS WITH ANTI-AGING / REVERSE-AGING EFFECT |
| WO2019138317A1 (en) * | 2018-01-15 | 2019-07-18 | Ciallella Giovanni | Nutraceutical composition for the activation of sirtuins with anti-aging/reverse-aging effect |
| US11484541B2 (en) | 2018-01-15 | 2022-11-01 | Sirtlife Corp. | Nutraceutical composition for the activation of sirtuins with anti-aging/reverse-aging effect |
| US11767314B2 (en) | 2018-11-02 | 2023-09-26 | Conopco, Inc. | Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same |
| US20240148026A1 (en) * | 2021-03-17 | 2024-05-09 | Hyo Gyoung Yu | Liquid-phase, supplementary feed composition containing coenzyme q10 |
| US12557829B2 (en) * | 2021-03-17 | 2026-02-24 | Hyo Gyoung Yu | Liquid-phase, supplementary feed composition containing coenzyme Q10 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR0207948A (en) | 2004-07-27 |
| ZA200307865B (en) | 2005-01-10 |
| US20040047896A1 (en) | 2004-03-11 |
| WO2002071874A3 (en) | 2003-01-09 |
| EA200300994A1 (en) | 2004-02-26 |
| NO20033941L (en) | 2003-09-05 |
| US20050100617A1 (en) | 2005-05-12 |
| EA006429B1 (en) | 2005-12-29 |
| NO20033941D0 (en) | 2003-09-05 |
| AU2008201296A1 (en) | 2008-04-17 |
| IL157367A (en) | 2006-07-05 |
| IL157367A0 (en) | 2004-02-19 |
| CA2439078C (en) | 2009-08-25 |
| KR20030088453A (en) | 2003-11-19 |
| CN1638650A (en) | 2005-07-13 |
| JP2004519241A (en) | 2004-07-02 |
| CA2439078A1 (en) | 2002-09-19 |
| MXPA03007802A (en) | 2003-12-08 |
| EP1372412A2 (en) | 2004-01-02 |
| PL363426A1 (en) | 2004-11-15 |
| AR032974A1 (en) | 2003-12-03 |
| PE20020987A1 (en) | 2002-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2439078C (en) | Composition improving age-related physiological deficits and increasing longevity | |
| CN1917779B (en) | Nutritional composition for improving skin condition and preventing skin diseases | |
| EP1213970B1 (en) | Method for improving the skin and coat of pets | |
| EP1492415B2 (en) | Method of improving absorption of vitamin e by a pet animal | |
| CA2351848C (en) | Method for increasing pet activity | |
| NO330469B1 (en) | Nutritional composition and use thereof. | |
| EP1637041B1 (en) | Improving longevity of elderly cats | |
| EP3537889B1 (en) | Pet food compositions | |
| AU2002308162A1 (en) | Composition improving age-related physiological deficits and increasing longevity | |
| HK1080688A (en) | Composition improving age-related physiological deficits and increasing longevity | |
| MXPA06008544A (en) | Nutritional composiition for improving skin condition and preventing skin diseases | |
| HK1098017A (en) | Nutritional composition for improving skin condition and preventing skin diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CA CN CO CR CZ DM EC HU ID IL IN JP KR LK MA MX NO NZ PH PL SG TN US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BR CA CN CO CR CZ DM EC HU ID IL IN JP KR LK MA MX NO NZ PH PL SG TN US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002750544 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 157367 Country of ref document: IL |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1-2003-500755 Country of ref document: PH |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2439078 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: PA/A/2003/007802 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1402/CHENP/2003 Country of ref document: IN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10656955 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002570843 Country of ref document: JP Ref document number: 1020037011809 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002308162 Country of ref document: AU Ref document number: 028062175 Country of ref document: CN |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2003/07865 Country of ref document: ZA Ref document number: 200307865 Country of ref document: ZA Ref document number: 200300994 Country of ref document: EA |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002750544 Country of ref document: EP |